Search clinical trials for: Anti-GD2 3F8 Monoclonal Antibody

Total 100221 results

Memorial Sloan Kettering Cancer Center

Completed

Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center

Completed

Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

Neuroblastoma | Bone Marrow, Sympathetic Nervous System

United States
Memorial Sloan Kettering Cancer Center

Completed

Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center; Children's Hospital Los Angeles; Y-mAbs Therapeutics

Active, not recruiting

Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma

Recurrent Osteosarcoma

United States
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics; Band of Parents

Completed

Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors

Neuroblastoma

United States
Zhujiang Hospital

Completed

Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma (4SCAR-GD2)

Effects of Immunotherapy | Neuroblastoma

China
St. Jude Children's Research Hospital
University of Wisconsin, Madison; Duke University; Children's Hospital Los Angeles and other collaborators

Completed

A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma

Melanoma | Osteosarcoma | Ewing Sarcoma | Neuroblastoma

United States
National Cancer Institute (NCI)

Completed

A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors

Melanoma | Sarcoma | Osteosarcoma | Neuroblastoma

United States
National University Hospital, Singapore

Unknown

Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells (NKEXPGD2)

Neuroblastoma Recurrent

Singapore
Shenzhen Geno-Immune Medical Institute

Unknown

Study on GD2 Positive Solid Tumors by 4SCAR-GD2

Solid Tumor

China
Shenzhen Second People's Hospital

Unknown

Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma

Multiple Myeloma in Relapse

China
St. Anna Kinderkrebsforschung
Charite University, Berlin, Germany; Istituto Giannina Gaslini; St. Anna Children...

Completed

ch14.18/CHO Bridging Study

Neuroblastoma

Italy, Austria, Germany
Abramson Cancer Center at Penn Medicine
Xencor, Inc.

Active, not recruiting

XmAb20717 in Advanced Biliary Tract Cancers

Biliary Tract Cancer

United States
BioMérieux

Completed

Impact of Differential and Systematic Diagnosis of Dengue, Chikungunya and Malaria on Patient Management and Antibiotic Use in West Africa

Malaria | Dengue | Chikungunya

Burkina Faso, Côte D'Ivoire
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Active, not recruiting

PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study

Melanoma | Sarcoma | Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center

Completed

High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation

Neuroblastoma

United States
Loewenstein Hospital
Meir Medical Center

Unknown

LMWH-VTE Prophylaxis for Survivors of Acute Ischemic Stroke- Assessment of Standard Dosing Regimen

Stroke

Israel
United Nations Office on Drugs and Crime (UNODC)
Polytechnique University of the Philippines; Anti-Drug Abuse Councils, LGUs...

Enrolling by invitation

Assessing the Feasibility of Providing a Family Skills Intervention "Strong Families" for Families in the Philippines. (SF_RCT_POPHL)

Family Relationship | Parenting Skills

Philippines
Cancer Research UK

Completed

A Phase I Trial of Anti-GD2 T-cells (1RG-CART)

Relapsed or Refractory Neuroblastoma

United Kingdom
PharmAbcine
Merck Sharp & Dohme LLC; Novotech (Australia) Pty Limited

Not yet recruiting

Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 (MarkV-01)

Advanced or Metastatic Solid Tumors

Australia
Bambino Gesù Hospital and Research Institute

Recruiting

GD2-CAR T Cells for Pediatric Brain Tumours

High Grade Glioma | Medulloblastoma, Childhood | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma | Embryonal Tumor | Brain Tumor Adult | Brain Tumor, Pediatric

Italy
Bambino Gesù Hospital and Research Institute

Recruiting

Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors

Sarcoma | Osteosarcoma | Ewing Sarcoma | Neuroblastoma | Neuroblastoma Recurrent | GD2-positive Solid Tumors

Italy
St. Jude Children's Research Hospital
Cookies for Kids' Cancer; CURE Childhood Cancer, Inc.

Active, not recruiting

Therapy for Children With Advanced Stage Neuroblastoma

Neuroblastoma

United States
University Children's Hospital Tuebingen

Completed

CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma

Neuroblastoma Recurrent

Germany, Austria
Margaret Gatti-Mays

Recruiting

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | HER2-Negative Breast Carcinoma

United States
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Active, not recruiting

Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

Neuroblastoma | High-Risk

United States
University Hospital, Bordeaux

Completed

PilBouTox® Project: Button Battery Poisoning From Data Collected by French Poison Control Centres (PILBOUTOX)

Button Battery Poisoning

France
R3 Stem Cell
R3 Medical Research

Recruiting

Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Lumbar Pain

Low Back Pain

United States
University of Oxford
National Institute for Health Research, United Kingdom; 180 Life Sciences

Completed

The Anti-Freaze-F Study- "Anti-TNF for Treatment of Frozen Shoulder - a Feasibility Study" (Anti-FreazeF)

Frozen Shoulder

United Kingdom
Kite, A Gilead Company
Arcellx, Inc.

Recruiting

Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma

Relapsed and Refractory Multiple Myeloma

United States
University College, London

Recruiting

Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma (MAGNETO)

Neuroblastoma

United Kingdom
University College, London

Recruiting

CAR T Cells to Target GD2 for DMG (CARMIGO)

Diffuse Midline Glioma, H3 K27M-Mutant

United Kingdom
UNC Lineberger Comprehensive Cancer Center
United States Department of Defense; Bellicum Pharmaceuticals

Recruiting

Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

Small Cell Lung Carcinoma | Lung Cancer | Non Small Cell Lung Cancer

United States
Sinobioway Cell Therapy Co., Ltd.
Children's Hospital of Fudan University; Nanjing Children's Hospital

Unknown

Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children

Relapsed or Refractory Neuroblastoma

China
Memorial Sloan Kettering Cancer Center

Completed

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

Sarcoma | Small Intestine Cancer | Ovarian Cancer | Lung Cancer | Brain and Central Nervous System Tumors | Metastatic Cancer | Neuroblastoma | Intraocular Melanoma | Melanoma (Skin) | Retinoblastoma

United States
Sun Yat-sen University
Hainan General Hospital

Recruiting

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Neuroblastoma

China
JLLC NatiVita
National Anti Doping Laboratory, Belarus

Not yet recruiting

The Bioequivalence Study of Two Sunitinib Products in Capsules 50 mg in Healthy Volunteers Under Fasting Conditions

Bioequivalence

Belarus
Pharmtechnology LLC
National Anti-Doping Labaratory

Completed

Bioequivalence Study of Sotalol, Tablets, 160 mg (Pharmtechnology LLC, Belarus), and Sotalex ®, Tablets, 160 mg (Bristol-Myers Squibb GmbH & Co. KGaA, Germany), in Healthy Volunteers Under Fasting Conditions

Bioequivalence

Belarus
Institut de Recherche pour le Developpement

Completed

Investigation of a Novel Approach to Improve Treatment Success Rates for Tuberculosis Patients in Senegal

Tuberculosis

Senegal
Texas Tech University

Completed

Adherence to Walking on an Alter G Anti-Gravity Treadmill

Severe Obesity

United States
Shenzhen Geno-Immune Medical Institute

Recruiting

GD2/CD70 Bi-specific CAR-T Cell Therapy

Cancer Disease

China
Shenzhen Geno-Immune Medical Institute

Recruiting

GD2/PSMA Bi-specific CAR-T Cell Therapy

Solid Tumor

China
Shenzhen Geno-Immune Medical Institute
Shenzhen Children's Hospital

Recruiting

4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma

Neuroblastoma

China
United Therapeutics

Terminated

A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients

Primary Refractory Neuroblastoma

United States
Centre Hospitalier Universitaire de Saint Etienne
Ministry of Health, France

Recruiting

Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders (THERAMAG)

Anti-MAG Neuropathy

France
Shenzhen Geno-Immune Medical Institute
The Seventh Affiliated Hospital of Sun Yat-sen University; Shenzhen Children...

Recruiting

Multi-CAR-T Cells Targeting B Cell Lymphomas

B Cell Lymphoma (BCL)

China
Y-mAbs Therapeutics

Terminated

Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers

Osteosarcoma | Neuroblastoma | Other Solid Tumor Cancers

United States
University Hospital, Montpellier

Completed

Impact of Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation (ImmunEO)

Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies

France
Anhui Provincial Hospital

Not yet recruiting

The Efficacy and Safety of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibodies Prior to Allo-HSCT

High Titers of Anti-HLA Antibody (MFI ≥5000)

China
Shenzhen Geno-Immune Medical Institute

Recruiting

GD2/CD56 Bi-specific CAR-T Cell Therapy

Malignant Disease

China

Search clinical trials for: Anti-GD2 3F8 Monoclonal Antibody

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations